Details of the Drug Combinations

General Information of This Drug (ID: DM1DX4Q)

• Drug Name: Eribulin (DM1DX4Q)

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Approved [1]; Liposarcoma; ICD 11: 2B59; Status: Approved [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

25 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Eribulin + Cyclophosphamide	DC08UFK	Cyclophosphamide	HER2 Negative Breast Cancer	[3]
Eribulin + Carboplatin	DC16WDP	Carboplatin	Estrogen Receptor-negative Breast Cancer	[4]
Eribulin + Capecitabine	DC98M4I	Capecitabine	Metastatic Breast Cancer	[5]
Eribulin + Carboplatin	DCKY07F	Carboplatin	Breast Cancer	[6]
Eribulin + Cyclophosphamide	DCXA0SI	Cyclophosphamide	Malignant Solid Tumour	[7]
Eribulin + Eribulin	DCD96VH	Eribulin	Tumor	[8]
Eribulin + Temozolomide	DCN7CE3	Temozolomide	Refractory Solid Tumors	[9]
Eribulin + Irinotecan	DC4BJY2	Irinotecan	Relapsed Solid Tumors	[10]
Eribulin + Lenvatinib	DC9R60D	Lenvatinib	Leiomyosarcoma	[11]
Eribulin + Irinotecan	DCD01D8	Irinotecan	Refractory or Recurrent Solid Tumors	[12]
Eribulin + Everolimus	DCMG5TF	Everolimus	Triple Negative Breast Cancer	[13]
Eribulin + PMID25656651-Compound-7	DCQCAR3	PMID25656651-Compound-7	Breast Cancer	[14]
Eribulin + PQR309	DCU6O2I	PQR309	Metastatic Breast Cancer	[15]
Eribulin + Everolimus	DCV4BXL	Everolimus	Estrogen Receptor Negative	[16]
Eribulin + ABT-888	DCHQSTE	ABT-888	Breast Cancer Stage IV	[17]
Eribulin + Capecitabine	DC404H3	Capecitabine	Metastatic Breast Cancer	[18]
Eribulin + Lenvatinib	DC95HHD	Lenvatinib	Cancer	[19]
Eribulin + GDC-0068	DCO7S95	GDC-0068	Triple Negative Breast Cancer	[20]
Eribulin + Al3818	DCQS7O6	Al3818	HER2-negative Breast Cancer	[21]
Eribulin + Gemcitabine	DCUQQ1R	Gemcitabine	Metastatic Breast Cancer	[22]
Eribulin + Gemcitabine	DC78YPN	Gemcitabine	Metastatic Breast Cancer	[23]
Eribulin + Gemcitabine	DC8M7UB	Gemcitabine	Metastatic Triple Negative Breast Cancer	[24]
Eribulin + Gemcitabine	DCHPHFG	Gemcitabine	Breast Cancer	[25]
Eribulin + Pazopanib	DCOST64	Pazopanib	Sarcoma,Soft Tissue	[26]
Eribulin + Capecitabine	DCUAJZ7	Capecitabine	Advanced Breast Cancer	[27]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6813).
• [2] Eribulin FDA Label
• [3] ClinicalTrials.gov (NCT01527487) Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
• [4] ClinicalTrials.gov (NCT01372579) Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
• [5] ClinicalTrials.gov (NCT01323530) A Confirmation Study of Eribulin in Combination With Capecitabine
• [6] ClinicalTrials.gov (NCT01795586) A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
• [7] ClinicalTrials.gov (NCT01554371) Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
• [8] ClinicalTrials.gov (NCT03002493) To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors
• [9] ClinicalTrials.gov (NCT06006273) A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
• [10] ClinicalTrials.gov (NCT02596503) A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
• [11] ClinicalTrials.gov (NCT03526679) Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
• [12] ClinicalTrials.gov (NCT03245450) Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
• [13] ClinicalTrials.gov (NCT02616848) Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
• [14] ClinicalTrials.gov (NCT02824575) Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
• [15] ClinicalTrials.gov (NCT02723877) PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
• [16] ClinicalTrials.gov (NCT02120469) Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
• [17] ClinicalTrials.gov (NCT03032614) Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
• [18] ClinicalTrials.gov (NCT05833919) Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
• [19] ClinicalTrials.gov (NCT02640508) Eribulin and Lenvatinib in Advanced Solid Tumors
• [20] ClinicalTrials.gov (NCT04464174) Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
• [21] ClinicalTrials.gov (NCT04624711) Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
• [22] ClinicalTrials.gov (NCT02263495) Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
• [23] ClinicalTrials.gov (NCT03901339) Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
• [24] ClinicalTrials.gov (NCT02555657) Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
• [25] ClinicalTrials.gov (NCT02574455) Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
• [26] ClinicalTrials.gov (NCT06263231) A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
• [27] ClinicalTrials.gov (NCT05063786) Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)